MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-14-2026
Cellectar Biosciences ROCE Ratio 2011-2026 | CLRB
Annual ROCE Ratio Cellectar Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -269.17 | -362.22 | 257.01 | -353.4 | -73.03 | -27.75 | -149.55 | -86.77 | -126.44 | -69.02 | -451.81 | -86.06 | -468.7 | -81.86 | -73.96 | -107.6 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 257.01 | -468.7 | -158.15 |
Quarterly ROCE Ratio Cellectar Biosciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -411.16 | -325.31 | -375.34 | -372.13 | -294.57 | -260.95 | -74.19 | -82.19 | 13.81 | -47.49 | -117.93 | -239.37 | -120.68 | -135.77 | -88.18 | -64.13 | -41.57 | -48.63 | -40.1 | -33.56 | -20.79 | -62.6 | -89.28 | -121.02 | -113.85 | -136.83 | -116.65 | -108.61 | -70.32 | -102.71 | -109.63 | -114.14 | -88.43 | -106.46 | -91.11 | -75.82 | -49.68 | -160.2 | -263.18 | -382.8 | -368.19 | -399.82 | -324.72 | -242.94 | -106.28 | -233.22 | -320.34 | -403.21 | -363.98 | -383.1 | -276.74 | -179.64 | -61.34 | -80.34 | -83.64 | -71.54 | -49.89 | -19.0 | -22.41 | -8.49 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.81 | -411.16 | -159.04 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-27.78 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
-7.08 | $ 93.93 | 1.82 % | $ 22.7 B | Germany |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.67 | 0.57 % | $ 249 M | Israel |
 |
Abcam plc
ABCM
|
-1.18 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-149.7 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-439.8 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.7 | -3.23 % | $ 173 M | USA |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-45.4 | - | - | $ 3.37 B | China |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.73 | 5.49 % | $ 203 M | USA |
 |
Anika Therapeutics
ANIK
|
-7.7 | $ 14.76 | -0.87 % | $ 212 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 31.6 | 2.43 % | $ 2.1 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.35 | -2.62 % | $ 5.51 M | Israel |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 21.7 | 2.79 % | $ 2.76 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |